IP Library Granted Patent US 8,715,230
Granted Patent B2
US 8,715,230 · App. 13/855,653 · Granted May 6, 2014

Balloon catheter systems for delivery of dry drug delivery vesicles to a vessel in the body

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,715,230
App. No.
13/855,653
Granted
May 6, 2014
Kind
B2
Abstract

Devices and methods for balloon delivery of rapamycin and other hydrophobic compounds to the wall of blood vessels. Balloon catheters, such as those used for balloon angioplasty, are modified with the addition of a reservoir of dry micelles, disposed at a suitable location within the balloon or catheter. The reservoir may be installed within the angioplasty balloon, within a lumen in communication with the angioplasty balloon, either as a loose or packed powder or as a film coating. The micelle preparation is reconstituted and the micelles are mobilized when the aqueous solution used to inflate the balloons is injected into the catheter. The micelles are infused into tissue surrounding the balloon when pressurized fluid within the balloon leaks through the wall of the balloon.

Claims (32)

1. A system for delivery of drugs or therapeutic agents to a blood vessel, said system comprising:

balloon catheter comprising a catheter body with a distal end adapted for insertion into the vasculature of a patient, a porous balloon disposed on the distal end, and a proximal end adapted for connection to a fluid source, and a lumen extending from the proximal end to the balloon;

a storage chamber with a reservoir of dry drug delivery vesicles;

an inflator;

a suspension chamber in fluid communication with an inflator;

a valve operable to selectively connect the suspension chamber to the storage chamber or the lumen of the catheter;

wherein the inflator is operable to fill the storage chamber with fluid to reconstitute the dry drug delivery vesicles into a fluid suspension of drug delivery vesicles and draw the fluid suspension into the suspension chamber, when the valve is positioned to connect the storage chamber to the suspension chamber, and the inflator is operable to force the suspension from the suspension chamber through the catheter lumen and porous balloon to the blood vessel.

2. A system of claim 1 , wherein the reservoir of dry drug delivery vesicles comprises micelles loaded with rapamycin or rapamycin analogs.

3. A system of claim 1 , wherein the reservoir of dry drug delivery vesicles comprises micelles loaded with ABT-578, zotarolimus, everolimus, biolimus A9, deforolimus, temsirolimus, tacrolimus, pimcrolimus, nitric oxide synthase, C3 exoenzyme, RhoA inhibitors, tubulusin, A3 agonists, CB2 agonists, 17-AAG, Hsp90 antagonists, tyrphostins, cathepsin S inhibitors, paclitaxel, dexamethasone, ceramides, dimethyl sphingosine, ether-linked diglycerides, ether-linked phosphatidic acids, sphinganines, estrogens, taxol, taxol analogs, actinomycin D, prostaglandins, vitamin A, probucol, Batimastat, Statins, Trapidil, mitomycin C or Cytochalasin B.

4. A system of claim 1 , wherein the suspension chamber comprises a tube with a diameter of 2 mm or less.

5. A system of claim 1 , wherein the suspension chamber comprises a coiled tube with a diameter of 1 to 2 mm, and overall length of about 300 mm.

6. The system of claim 1 , wherein the valve is a three way valve interposed between the storage chamber and the suspension chamber, and is operable to align the storage chamber and the suspension chamber in fluid communication, and is also disposed between the catheter and the suspension chamber, and is operable to align the catheter lumen and suspension chamber in fluid communication.

7. The system of claim 1 , further comprising a catheter handle disposed on the proximal end of the catheter, wherein the storage chamber and the suspension chamber are disposed within the handle.

8. The system of claim 1 , wherein the suspension chamber is disposed in fluid communication between the valve and the inflator.

9. The system of claim 1 , wherein the storage chamber is disposed in fluid communication between the valve and the inflator.

10. The system of claim 1 , wherein the storage chamber and the suspension chamber are disposed in fluid communication between the valve and the inflator.

11. A system for delivery of drugs or therapeutic agents to a blood vessel, said system comprising:

balloon catheter comprising a catheter body with a distal end adapted for insertion into the vasculature of a patient, a porous balloon disposed on the distal end, and a proximal end adapted for connection to a fluid source, and a lumen extending from the proximal end to the balloon;

a FIRST chamber with a reservoir of dry drug delivery vesicles;

an inflator;

a second chamber in fluid communication with an inflator;

a valve operable to selectively connect the second chamber to the first chamber or the lumen of the catheter;

wherein the inflator is operable to fill the FIRST chamber with fluid to reconstitute the dry drug delivery vesicles into a fluid suspension of drug delivery vesicles and draw the fluid suspension into the SECOND chamber, when the valve is positioned to connect the FIRST chamber to the SECOND chamber, and the inflator is operable to force the suspension from the SECOND chamber through the catheter lumen and porous balloon to the blood vessel.

12. A system of claim 9 , wherein the reservoir of dry drug delivery vesicles comprises micelles loaded with rapamycin or rapamycin analogs.

13. A system of claim 9 , wherein the reservoir of dry drug delivery vesicles comprises micelles loaded with ABT-578, zotarolimus, everolimus, biolimus A9, deforolimus, temsirolimus, tacrolimus, pimcrolimus, nitric oxide synthase, C3 exoenzyme, RhoA inhibitors, tubulusin, A3 agonists, CB2 agonists, 17-AAG, Hsp90 antagonists, tyrphostins, cathepsin S inhibitors, paclitaxel, dexamethasone, ceramides, dimethyl sphingosine, ether-linked diglycerides, ether-linked phosphatidic acids, sphinganines, estrogens, taxol, taxol analogs, actinomycin D, prostaglandins, vitamin A, probucol, Batimastat, Statins, Trapidil, mitomycin C or Cytochalasin B.

14. A system of claim 11 , wherein the suspension chamber comprises a tube with a diameter of 2 mm or less.

15. A system of claim 11 , wherein the suspension chamber comprises a coiled tube with a diameter of 1 to 2 mm, and overall length of about 300 mm.

16. The system of claim 11 , wherein the valve is a three way valve interposed between the storage chamber and the suspension chamber, and is operable to align the storage chamber and the suspension chamber in fluid communication, and is also disposed between the catheter and the suspension chamber, and is operable to align the catheter lumen and suspension chamber in fluid communication.

17. The system of claim 11 , further comprising a catheter handle disposed on the proximal end of the catheter, wherein the storage chamber and the suspension chamber are disposed within the handle.

18. The system of claim 11 , wherein the suspension chamber is disposed in fluid communication between the valve and the inflator.

19. The system of claim 11 , wherein the storage chamber is disposed in fluid communication between the valve and the inflator.

20. The system of claim 11 , wherein the storage chamber and the suspension chamber are disposed in fluid communication between the valve and the inflator.

Assignments (9)
SECURITY INTEREST Recorded Aug 7, 2025
From: ORCHESTRA BIOMED HOLDINGS, INC.; ORCHESTRA BIOMED, INC.; BACKBEAT MEDICAL, LLC; CALIBER THERAPEUTICS, LLC
To: MEDTRONIC, INC.
Reel/Frame 072341/0075 →
SECURITY INTEREST Recorded Aug 4, 2025
From: ORCHESTRA BIOMED HOLDINGS, INC.; ORCHESTRA BIOMED, INC.; BACKBEAT MEDICAL, LLC; CALIBER THERAPEUTICS, LLC
To: LIGAND PHARMACEUTICALS, INC.
Reel/Frame 072359/0219 →
SECURITY INTEREST Recorded Nov 6, 2024
From: ORCHESTRA BIOMED HOLDINGS, INC.; ORCHESTRA BIOMED, INC.; CALIBER THERAPEUTICS, LLC; BACKBEAT MEDICAL, LLC; FREEHOLD SURGICAL, LLC
To: HERCULES CAPITAL, INC.
Reel/Frame 069312/0758 →
RELEASE OF IP SECURITY INTEREST Recorded Oct 9, 2023
From: AVENUE VENTURE OPPORTUNITIES FUND, L.P.
To: ORCHESTRA BIOMED, INC.; CALIBER THERAPEUTICS, LLC; BACKBEAT MEDICAL, LLC; FREEHOLD SURGICAL, LLC; ACCELERATED TECHNOLOGIES, INC.
Reel/Frame 065192/0001 →
SECURITY AGREEMENT Recorded Jun 6, 2022
From: ORCHESTRA BIOMED, INC.; CALIBER THERAPEUTICS, LLC; BACKBEAT MEDICAL, LLC; FREEHOLD SURGICAL, LLC; ACCELERATED TECHNOLOGIES, INC.
To: AVENUE VENTURE OPPORTUNITIES FUND, L.P., AS AGENT
Reel/Frame 060286/0021 →
ENTITY CONVERSION Recorded Feb 12, 2020
From: CALIBER THERAPEUTICS, INC.
To: CALIBER THERAPEUTICS, LLC
Reel/Frame 051911/0718 →
RELEASE OF SECURITY INTEREST Recorded Jun 13, 2017
From: ORCHESTRA MEDICAL VENTURES II, L.P.
To: CALIBER THERAPEUTICS, INC.
Reel/Frame 042695/0937 →
SECURITY INTEREST Recorded Jan 20, 2016
From: CALIBER THERAPEUTICS, INC.
To: ORCHESTRA MEDICAL VENTURES II, L.P.; THE PEIERLS GROUP; ORCHESTRA CALIBER CO-INVESTMENT PARTNERS, LLC; ASCENT BIOMEDICAL VENTURES II, LP; ASCENT BIOMEDICAL VENTURES SYNECOR, LP
Reel/Frame 037532/0524 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 22, 2013
From: BAUMBACH, PH.D., WILLIAM R.; SHERMAN, DARREN R.; BURGERMEISTER, ROBERT S.
To: CALIBER THERAPEUTICS, INC.
Reel/Frame 030850/0484 →